28th February 2024

At the Pelvic Radiation Disease Association, we regularly receive enquiries regarding HBOT in relation to the treatment of Pelvic Radiation Disease symptoms. The Best Practice Pathway for Pelvic Radiation Disease, published in 2022, refers to Hyperbaric Oxygen Therapy in the management of Gastrointestinal symptoms (page 39), Urinary symptoms (page 51) and Skin Problems (radiation ulceration and poor wound healing) (page 135).

The support provided by PRDA does not replace professional care and we are unable to offer medical advice. We suggest, therefore, that you seek advice from your doctor to discuss HBOT as a possible treatment option. 


Since the launch of our Best Practice Pathway, findings from a systematic review has been published on hyperbaric oxygen therapy (HBOT) as a treatment for individuals who developed late radiation-induced tissue toxicity (LRITT) for gynaecological cancers.

Hyperbaric oxygen treatment for late radiation-induced tissue toxicity in treated gynaecological cancer patients: a systematic review – PMC (nih.gov)

Healthcare Professionals wishing to refer a patient for HBOT can contact DDRC Healthcare www.ddrc.org for advice on whether/how a referral may be possible.  Please see below for the NHS England clinical commissioning policy for HBOT.